Want to see DCOY full AI Analyst Report?
DCOY Stock Chart & Stats
$2.97
-$0.06(-3.48%)
At close: 4:00 PM EST
$2.97
-$0.06(-3.48%)
Day’s Range― - ―
52-Week Range$0.96 - $47.64
Previous CloseN/A
VolumeN/A
Average Volume (3M)4.58M
Market Cap
$2.31M
Enterprise Value-$4.66T
Total Cash (Recent Filing)$8.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.19
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding2,385,282
10 Day Avg. Volume67,684
30 Day Avg. Volume4,576,610
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.64
Price to Sales (P/S)0.00
P/FCF Ratio-0.78
Enterprise Value/Market Cap-2.01M
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit546.61K
Enterprise Value/Ebitda322.73K
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of material debt reduces solvency and refinancing pressure while the company funds research. This gives management more flexibility than a leveraged biotech to direct available capital toward development, although it does not eliminate the need for future financing.
Recent Liquidity ImprovementThe recent proceeds provide additional working capital for ongoing operations and may extend the company’s ability to execute its research program over the next several months. This improves near-term financial flexibility, even though the financing also creates dilution exposure.
Focused Therapeutic PlatformA focused decoy-based research strategy can concentrate a small organization’s scientific and financial resources around a defined therapeutic approach. That specialization supports continuity in the development model and may help management prioritize candidates across related biological targets.
Bears Say
Pre-revenue Business ModelThe absence of revenue leaves the company dependent on financing rather than internally generated operating income. Until a candidate reaches commercialization, development spending is unlikely to be self-funded, making execution milestones and access to capital central to business durability.
Persistent Cash BurnSustained negative operating and free cash flow shows that research and corporate activities continue to consume cash. This reduces financial resilience, limits the ability to fund development internally, and increases the importance of repeated external financing over the next several quarters.
Equity Erosion And Dilution RiskThe sharp decline in equity indicates that losses have consumed much of the capital base, while the newly issued warrants add potential share dilution. Together, these factors can weaken per-share ownership and leave less financial capacity to absorb continued development losses.
Decoy Therapeutics News
DCOY FAQ
What was Decoy Therapeutics’s price range in the past 12 months?
Decoy Therapeutics lowest stock price was $0.96 and its highest was $47.64 in the past 12 months.
What is Decoy Therapeutics’s market cap?
Decoy Therapeutics’s market cap is $2.31M.
When is Decoy Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Decoy Therapeutics’s earnings last quarter?
Currently, no data Available
Is Decoy Therapeutics overvalued?
According to Wall Street analysts Decoy Therapeutics’s price is currently Overvalued.
Does Decoy Therapeutics pay dividends?
Decoy Therapeutics does not currently pay dividends.
What is Decoy Therapeutics’s EPS estimate?
Decoy Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Decoy Therapeutics have?
Decoy Therapeutics has 2,385,282 shares outstanding.
What happened to Decoy Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Decoy Therapeutics?
Currently, no hedge funds are holding shares in DCOY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Decoy Therapeutics
Based in Cambridge, Massachusetts, Decoy Therapeutics Inc. is an early-stage biotechnology firm dedicated to tackling critical unmet medical needs. The company employs cutting-edge machine learning and AI technologies, alongside accelerated synthesis methods, to swiftly design, engineer, and manufacture innovative peptide conjugate drug candidates.